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EDITORIAL COMMENT
Dobutamine and the
Coronary Vasomotion Paradox*
Morton J. Kern, MD, FACC
St. Louis, Missouri
Dobutamine, a structural relative of dopamine, acts directly
on alpha- and beta-adrenergic receptors without the release
of norepinephrine or activation of dopaminergic receptors.
For clinical use, dobutamine is a racemic mixture of a
levo-isomer acting as a potent alpha-1 agonist and a
dextro-isomer counterbalancing this effect as an alpha-1
antagonist. Both isomers are complete beta-receptor ago-
nists with the dextro-isomer 10-fold more potent than the
levo-isomer (1). Intravenous dobutamine is widely used to
determine the significance of coronary atherosclerotic dis-
ease (2) and to support the myocardium during heart failure
(3). Depending on dose, dobutamine has been demon-
strated to evoke myocardial ischemia and identify myocar-
dial hibernation and viability (4,5).
See page 1596
Dobutamine’s major mechanisms, increasing inotropy
and chronotropy, are produced principally but not exclu-
sively through the activation of the adrenergic receptor
system, which stimulates myocardial oxygen demand (6). In
the setting of limited coronary blood flow, the heightened
adrenergic response tips the balance of the myocardial
oxygen supply and demand equation toward ischemia.
While increasing contractility, dobutamine also decreases
microvascular resistance (7), simultaneously activating ad-
ditional vascular receptors, depending on the presence or
absence of a normally functioning endothelium (8). In
experimental animals, dobutamine produces vasodilation
through a net balance between an endothelial flow-
mediated vasodilation in response to increased metabolic
demand and the direct stimulation of vascular and cardiac
beta-1 and beta-2 adrenergic receptors. These vasodilatory
forces are counteracted by the vasoconstrictive effects of
dobutamine-stimulated alpha-1 adrenergic receptors within
the vessel wall (9).
This potential multiplicity of vascular mechanisms has
given rise to a question about dobutamine and paradoxical
coronary vasomotor responses. For example, why does
dobutamine-induced stress testing produce more false neg-
atives than direct hemodynamic assessment of coronary
stenoses (10)? Additionally, physical exercise induces coro-
nary vasodilation in normal arteries but paradoxically vaso-
constricts diseased coronary arteries with endothelial dys-
function (11). Does dobutamine vasodilate atherosclerotic
epicardial coronary arteries?
In this tissue of the Journal, Barbato et al. (12) elegantly
addressed the question of dobutamine and coronary vaso-
motion in humans and which receptor mechanisms might
be involved. The ambitious well-designed protocol studied
six groups of patients with quantitative coronary angiogra-
phy during escalating infusions of dobutamine. Intravenous
dobutamine, in doses from 10 to 40 g/kg/min, was given
to 19 normal patients (group 1), 23 patients with mild
atherosclerotic artery disease (group 3), and 12 patients with
severely stenotic arteries (group 4). Saline infusions were
used in 8 control patients (group 2). Dobutamine infusions
were preceded by the alpha-blocker phentolamine (12
g/kg) in 12 patients (group 5) or the nitric oxide substrate
L-arginine (150 g/min) in 11 patients (group 6) followed
by the dobutamine infusions as performed in groups 1, 3,
and 4. Patients in groups 5 and 6 both had severely diseased
arteries.
The investigators found that, for identical increases in the
heart rate–pressure product, dobutamine induced coronary
vasodilation of 19% in normals, 8% in mildly atherosclerotic
arteries, and produced no vasomotion in the severely ste-
notic arteries (3%). This failure to vasodilate was partially
improved to 10% by L-arginine and fully restored to 19% by
phentolamine in the severely diseased coronary artery pa-
tients. These findings indicated that a combination of
endothelial dysfunction and enhanced alpha-adrenergic
tone contributed to the failure of dobutamine to induce
atherosclerotic coronary arteries to dilate. Of importance,
unlike reports of exercise coronary vasomotion, a paradox-
ical vasoconstriction during dobutamine infusion did not
occur.
The study cited (12) should be viewed as a paradigm in
the examination of coronary physiologic responses to phar-
macologic challenge. The investigators should be congrat-
ulated for adherence to a rigorous protocol, which notably
included agents to dissect and test postulated mechanisms of
vascular receptor activity in both normal and diseased
coronary arteries. These responses are of interest because
dobutamine directly stimulates alpha-1, beta-1, and beta-2
adrenergic receptors within the vessel wall (13) with beta-
adrenergic vasorelaxation being partly mediated by nitric
oxide activation—that is, normal endothelial function of
both conductance and resistance circuits (14). Some inves-
tigators believe that endothelial function plays a relatively
minor role in enhancing vasodilation through a flow-
mediated mechanism, whereas beta-receptor activation is a
more powerful epicardial coronary vasodilator (15). Because
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beta-1 and beta-2 adrenergic receptors on the coronary
vasculture are distributed in a heterogeneous fashion, beta-1
receptors appear crucial to epicardial coronary vasomotion,
whereas beta-2 receptors are more important to the smaller
resistance arteriolar function. Activation of these receptors
also increases contractility and oxygen consumption, poten-
tiating the release of vasodilatory substances, acting inde-
pendently of endothelial function. In this setting, adenosine
appears to be one of the prototypical stimulatory agents
affecting both epicardial arteries and, to a greater degree, the
microvasculature (16).
In theory, beta-adrenergic blockade could paradoxically
cause myocardial ischemia through unopposed alpha-
adrenergic vasoconstriction in coronary disease patients
when subjected to mixed adrenergic stimuli (17,18). In
contrast to normal artery responses, exercise-induced vaso-
constriction is attributed to the atherosclerotic dysregulation
of endothelium, accentuated in the presence of hypercho-
lesterolemia, hypertension, and smoking. Further demon-
strations of this mechanism are gleaned from studies of cold
pressor testing, mental stress, and atrial pacing, which
similarly produce alpha-mediated vasoconstrictor responses
in patients along a gradient of increasingly severe endothe-
lial dysfunction.
In the Barbato et al. study (12), dobutamine had minimal
(3% change in luminal diameter) vasoconstrictive effects
seen only at the lowest dose in the severely stenotic artery
patient groups. The absence of vasoconstriction or dilation
during dobutamine in these patient groups was not due to
vessel stiffness as all arteries dilated with exposure to
intracoronary isosorbide dinitrate. Apparently, some vascu-
lar smooth muscle remains functional even in some highly
diseased vessels, suggesting vasomotor responses persist and
are mediated directly through nitric oxide release, and/or
indirectly through the alpha- and beta-adrenergic receptor
interaction.
As with all complex protocols, the inherent limitations
are worth reviewing. Concomitant medical therapy may
attenuate coronary vasomotor responses to any pharmaco-
logic or physiologic challenges. For example, angiotensin-
converting enzyme inhibitors and statins, which may im-
prove endothelial function, could potentiate a vasodilatory
response. No medication differences were observed among
the six patient groups. Also, some investigators note that
diurnal variations of vasomotor responses may be a substan-
tial confounding influence in a study such as this (19).
Finally, the methodology of using quantitative coronary
angiography has inherent limitations in detecting small
differences in vessel dimensions, especially lumen diameter
for calculation of cross-sectional area, and may be influenced
by the timing, imaging technique, and method of injection.
Over a large patient series, these differences would be
minimal and not likely to lead to a systematic error.
The action of dobutamine on the coronary artery is
ultimately the net result of the interplay of alpha- and
beta-adrenergic receptors (Table 1) and endothelial func-
tion. In a dose-dependent manner, dobutamine vasodilates
normal and mildly atherosclerotic arteries, whereas in se-
verely diseased arteries, paradoxical alpha-adrenergic vaso-
constriction is not observed to any significant degree.
Barbato et al. (12) advance our understanding and interpre-
tation of dobutamine stress testing and its relationship to
coronary blood flow in patients with coronary artery disease.
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